Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suzetrigine in Diabetic Peripheral Neuropathic Pain
NCT06628908Phase 3Recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of suzetrigine in diabetic polyneuropathy (DPN), sponsored by Vertex Pharmaceuticals. Started Oct 2024; status: recruiting.
02
Drugs
suzetrigine
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT06628908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06628908.